Data gathered: February 8
AI Stock Analysis - Karyopharm Therapeutics (KPTI)
Analysis generated January 31, 2025. Powered by Chat GPT.
Karyopharm Therapeutics Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other diseases. The company's leading product, XPOVIO (selinexor), is an oral Selective Inhibitor of Nuclear Export (SINE) compound. The company's headquarters is in Newton, Massachusetts.
Stock Alerts - Karyopharm Therapeutics (KPTI)
 |
Karyopharm Therapeutics | February 7 Price is down by -5.3% in the last 24h. |
|
Karyopharm Therapeutics | February 6 Price is down by -5.6% in the last 24h. |
|
Karyopharm Therapeutics | February 6 Insider Alert: Paulson Richard A. is selling shares |
|
Karyopharm Therapeutics | February 5 Price is up by 6.1% in the last 24h. |
Alternative Data for Karyopharm Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 12 | Sign up | Sign up | Sign up |
| Sentiment | 96 | Sign up | Sign up | Sign up |
| Webpage traffic | 7,000 | Sign up | Sign up | Sign up |
| Employee Rating | 84 | Sign up | Sign up | Sign up |
| Google Trends | 85 | Sign up | Sign up | Sign up |
| Patents | 31 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | N/A | Sign up | Sign up | Sign up |
| Facebook Followers | 879 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 4 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 7,864 | Sign up | Sign up | Sign up |
| Twitter Followers | 1,550 | Sign up | Sign up | Sign up |
| Twitter Mentions | 29 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 73 | Sign up | Sign up | Sign up |
| Linkedin Employees | 384 | Sign up | Sign up | Sign up |
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases.
| Price | $0.63 |
| Target Price | Sign up |
| Volume | 725,480 |
| Market Cap | $80M |
| Year Range | $0.6 - $1.1 |
| Dividend Yield | 0% |
| Analyst Rating | 83% buy |
| Industry | Biotechnology |
In the news
 |
Karyopharm Therapeutics (NASDAQ:KPTI) Shares Pass Below Two Hundred Day Moving Average – Time to Sell?February 5 - ETF Daily News |
|
Barclays PLC Sells 777,507 Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI)January 25 - ETF Daily News |
|
HC Wainwright Has Negative Outlook of KPTI FY2024 EarningsJanuary 17 - ETF Daily News |
 |
Why Karyopharm Therapeutics (KPTI) Is Among the Best Penny Stocks to Invest In According to Media?January 6 - Yahoo |
|
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Holdings Decreased by State Street CorpJanuary 4 - ETF Daily News |
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)January 2 - Finnhub |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 39M | 28M | 11M | -32M | -21M | -0.257 |
| Q2 '24 | 87M | 31M | 56M | 24M | 33M | 0.150 |
| Q1 '24 | 27M | 30M | -2.3M | -37M | -31M | -0.320 |
| Q4 '23 | 28M | 31M | -3.1M | -42M | -35M | -0.360 |
| Q3 '23 | 30M | 31M | -870,000 | -35M | -28M | -0.300 |
Insider Transactions View All
| Paulson Richard A. filed to sell 1,120,158 shares at $0.7. February 5 '25 |
| Paulson Richard A. filed to sell 1,124,257 shares at $0.8. January 7 '25 |
| Paulson Richard A. filed to sell 1,128,312 shares at $0.8. December 5 '24 |
| Paulson Richard A. filed to sell 1,131,932 shares at $0.9. November 6 '24 |
| Paulson Richard A. filed to sell 1,135,607 shares at $0.9. October 7 '24 |
Similar companies
Read more about Karyopharm Therapeutics (KPTI) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Karyopharm Therapeutics?
The Market Cap of Karyopharm Therapeutics is $80M.
What is the current stock price of Karyopharm Therapeutics?
Currently, the price of one share of Karyopharm Therapeutics stock is $0.63.
How can I analyze the KPTI stock price chart for investment decisions?
The KPTI stock price chart above provides a comprehensive visual representation of Karyopharm Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Karyopharm Therapeutics shares. Our platform offers an up-to-date KPTI stock price chart, along with technical data analysis and alternative data insights.
Does KPTI offer dividends to its shareholders?
As of our latest update, Karyopharm Therapeutics (KPTI) does not offer dividends to its shareholders. Investors interested in Karyopharm Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Karyopharm Therapeutics?
Some of the similar stocks of Karyopharm Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.